[go: up one dir, main page]

AU2001246999A1 - New neurokinin antagonists for use as medicaments - Google Patents

New neurokinin antagonists for use as medicaments

Info

Publication number
AU2001246999A1
AU2001246999A1 AU2001246999A AU4699901A AU2001246999A1 AU 2001246999 A1 AU2001246999 A1 AU 2001246999A1 AU 2001246999 A AU2001246999 A AU 2001246999A AU 4699901 A AU4699901 A AU 4699901A AU 2001246999 A1 AU2001246999 A1 AU 2001246999A1
Authority
AU
Australia
Prior art keywords
medicaments
neurokinin antagonists
new
new neurokinin
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001246999A
Inventor
Jeffrey Scott Albert
Peter Bernstein
Cyrus Ohnmacht Jr.
Keith Russell
Ashokkumar Bhikkappa Shenvi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0008728A external-priority patent/GB0008728D0/en
Priority claimed from GB0008727A external-priority patent/GB0008727D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2001246999A1 publication Critical patent/AU2001246999A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A compound having the general formula (I) and methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.
AU2001246999A 2000-04-06 2001-04-05 New neurokinin antagonists for use as medicaments Abandoned AU2001246999A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US19536500P 2000-04-06 2000-04-06
US19517700P 2000-04-06 2000-04-06
US60195177 2000-04-06
US60195365 2000-04-06
GB0008727 2000-04-11
GB0008728A GB0008728D0 (en) 2000-04-11 2000-04-11 Compounds
GB0008727A GB0008727D0 (en) 2000-04-11 2000-04-11 Compounds
GB0008728 2000-04-11
PCT/SE2001/000754 WO2001077089A1 (en) 2000-04-06 2001-04-05 New neurokinin antagonists for use as medicaments

Publications (1)

Publication Number Publication Date
AU2001246999A1 true AU2001246999A1 (en) 2001-10-23

Family

ID=27447827

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001246999A Abandoned AU2001246999A1 (en) 2000-04-06 2001-04-05 New neurokinin antagonists for use as medicaments

Country Status (7)

Country Link
EP (1) EP1276729B1 (en)
JP (1) JP2003530388A (en)
AT (1) ATE400563T1 (en)
AU (1) AU2001246999A1 (en)
DE (1) DE60134735D1 (en)
ES (1) ES2307605T3 (en)
WO (1) WO2001077089A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0003476D0 (en) * 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
SE0201938D0 (en) * 2002-06-20 2002-06-20 Astrazeneca Ab New process
US8168635B2 (en) * 2004-06-19 2012-05-01 Human Biomolecular Research Institute Modulators of central nervous system neurotransmitters
RU2383536C2 (en) 2004-08-04 2010-03-10 Тайсо Фармасьютикал Ко., Лтд. Triazole derivative
JP5035752B2 (en) 2006-02-03 2012-09-26 大正製薬株式会社 Triazole derivative
CN101415687B (en) 2006-02-06 2012-02-08 大正制药株式会社 Binding inhibitor of sphingosine-1-phosphate
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CN101790517B (en) 2007-08-01 2013-08-21 大正制药株式会社 Substances that inhibit S1P1 binding
NO2729147T3 (en) 2011-07-04 2018-02-03
ES2980110T3 (en) 2018-02-26 2024-09-30 Ospedale San Raffaele Srl NK-1 antagonists for use in the treatment of ocular pain
RU2697414C1 (en) 2018-05-11 2019-08-14 Общество с ограниченной ответственностью "АЙ БИ ДИ Терапевтикс" Novel tachykinin receptor antagonist and use thereof
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9505084D0 (en) * 1995-03-14 1995-05-03 Pfizer Ltd Benzamide derivative
CN1309638A (en) * 1998-07-10 2001-08-22 阿斯特拉曾尼卡有限公司 N-substituted naphthylcarboxamides as neurokinin receptor antagonists
GB9922519D0 (en) * 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9922521D0 (en) * 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9826941D0 (en) * 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
FR2792835B3 (en) * 1999-04-27 2001-05-25 Sanofi Sa USE OF SAREDUTANT FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OR PREVENTION OF ALL MOOD DISORDERS, ADAPTATION DISORDERS OR MIXED ANXIETY-DEPRESSION DISORDERS

Also Published As

Publication number Publication date
WO2001077089A1 (en) 2001-10-18
JP2003530388A (en) 2003-10-14
ES2307605T3 (en) 2008-12-01
EP1276729A1 (en) 2003-01-22
EP1276729B1 (en) 2008-07-09
ATE400563T1 (en) 2008-07-15
DE60134735D1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
AU7031500A (en) Therapeutic quinazoline compounds
PT1263725E (en) NEW COMPOUNDS
GB9914486D0 (en) Medicaments
ATE316083T1 (en) ADAMANTANDE DERIVATIVES
IL164974A0 (en) Novel compounds and their use
AU3850600A (en) Dalda analogs and their use
DE602004011966D1 (en) Heterocyclylverbindungen
GB0109122D0 (en) Novel compounds
NO20020282L (en) New diphenyl-piperidine derivative
WO2003087049A3 (en) Pharmaceutical combinations containing heterocyclic compounds and a novel anticholinergic agent
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
MXPA05005790A (en) Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders.
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
MXPA04005809A (en) Protein kinase inhibitors.
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
MXPA04005484A (en) Method for preparing echinocandin derivatives.
AU7270798A (en) Antithrombotic agents
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
SE0004827D0 (en) Therapeutic compounds
GB0019008D0 (en) Therapeutic compounds
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
EP1027051A4 (en) Antithrombotic agents